News for Precision BioSciences, Inc. (DTIL)

The Food and Drug Administration (FDA) has awarded orphan drug designation to a new therapeutic approach for Duchenne muscular dystrophy, which is being develop

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene edit

Precision BioSciences (DTIL) has shared new preclinical findings that bolster the rationale for rapid advancement of their PBGENE-DMD gene editing treatment for

On June 25, 2025, Kevin Buehler, a Director at Precision BioSciences Inc (DTIL), purchased 5,076 shares of the company. Following this transaction, the insider

On May 21, 2025, HC Wainwright & Co. reiterated their bullish stance on Precision BioSciences (DTIL), maintaining its "Buy" rating. This decision reflects the f

Revenue: Less than $0.1 million for Q1 2025, significantly below the estimated $5.00 million and a sharp decline from $17.6 million in Q1 2024.Net Loss: $20.6

Precision BioSciences (DTIL) reported an impressive first-quarter revenue of $29,000, significantly surpassing the $5 million consensus. The company is making h

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene edit

Precision BioSciences (DTIL) kicked off 2025 with a notable revenue report of $29,000, significantly surpassing the projected $5 million consensus. The company

Precision BioSciences (DTIL) reports first quarter 2025 financial results, showing a net loss of $20.6 million or $(2.21) per share. Encouraging initial

Precision BioSciences (DTIL) reports Q1 GAAP EPS of -$2.21, missing estimates by $0.49.

Precision BioSciences (DTIL) Q1 earnings release on May 15 showcases expected EPS of -$2.42 & revenue of $5M.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene edit

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene edit

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

Shares of Precision BioSciences, Inc. DTIL rose sharply in today's pre-market trading. Precision BioSciences reported clearance of investigational new drug app...

**media[555305]**

Precision BioSciences (NASDAQ:DTIL) stock gains as company reports promising Phase 1 trial results for its Hepatitis B gene therapy, PBGENE-HBV. Read more here.

On December 31, 2024, Aquilo Capital Management, LLC (Trades, Portfolio) made a significant move by acquiring an additional 410,059 shares of Precision BioScien